CD8A and brain neoplasm: Therefore, in such pathological contexts, one could expect that NKG2D-controled antitumor Vγ9Vδ2 T cell reactivities would be altered by TGF-β which transcription is elevated in brain tumors (27, 28) as previously described for NK and CD8+ T cells (29).